CN112867489A - Sarm1抑制剂 - Google Patents
Sarm1抑制剂 Download PDFInfo
- Publication number
- CN112867489A CN112867489A CN201980052440.2A CN201980052440A CN112867489A CN 112867489 A CN112867489 A CN 112867489A CN 201980052440 A CN201980052440 A CN 201980052440A CN 112867489 A CN112867489 A CN 112867489A
- Authority
- CN
- China
- Prior art keywords
- compound
- aliphatic
- formula
- sarm1
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510537996.8A CN120398784A (zh) | 2018-06-07 | 2019-06-06 | Sarm1抑制剂 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682054P | 2018-06-07 | 2018-06-07 | |
| US62/682,054 | 2018-06-07 | ||
| PCT/US2019/035846 WO2019236890A1 (en) | 2018-06-07 | 2019-06-06 | Inhibitors of sarm1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510537996.8A Division CN120398784A (zh) | 2018-06-07 | 2019-06-06 | Sarm1抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112867489A true CN112867489A (zh) | 2021-05-28 |
Family
ID=68770700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980052440.2A Pending CN112867489A (zh) | 2018-06-07 | 2019-06-06 | Sarm1抑制剂 |
| CN202510537996.8A Pending CN120398784A (zh) | 2018-06-07 | 2019-06-06 | Sarm1抑制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510537996.8A Pending CN120398784A (zh) | 2018-06-07 | 2019-06-06 | Sarm1抑制剂 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12624026B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3801503A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7481329B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN112867489A (cg-RX-API-DMAC7.html) |
| MA (1) | MA52812A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019236890A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023193809A1 (zh) * | 2022-04-08 | 2023-10-12 | 深圳众格生物科技有限公司 | Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1阻害剤 |
| CA3102645A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CN112955150A (zh) * | 2018-10-19 | 2021-06-11 | 达萨玛治疗公司 | 与nad+或nad+前体组合的sarm1抑制剂 |
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| US12624025B2 (en) * | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| JP7319395B2 (ja) | 2019-06-14 | 2023-08-01 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1の阻害剤 |
| WO2021050913A1 (en) | 2019-09-12 | 2021-03-18 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| WO2021108602A1 (en) * | 2019-11-26 | 2021-06-03 | Disarm Therapeutics, Inc. | Methods and compositions for neuroprotection |
| EP4083037A4 (en) * | 2019-12-26 | 2024-01-24 | Yonsei University, University-Industry Foundation(UIF). | Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same |
| AU2021206651B2 (en) * | 2020-01-07 | 2024-02-22 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| CA3174321A1 (en) | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
| WO2021207308A1 (en) | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Condensed pyrazole derivatives as inhibitors of sarm1 |
| EP4192828A1 (en) | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| TW202334117A (zh) | 2020-08-24 | 2023-09-01 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| WO2022060812A1 (en) * | 2020-09-16 | 2022-03-24 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| CN117797146A (zh) * | 2020-11-12 | 2024-04-02 | 科辉智药生物科技(无锡)有限公司 | Sarm1酶活性抑制剂及其在神经退行性疾病中的应用 |
| CA3200439A1 (en) * | 2020-12-08 | 2022-06-16 | Disarm Therapeutics, Inc. | Benzopyrazole inhibitors of sarm1 |
| KR20240041987A (ko) | 2021-07-28 | 2024-04-01 | 누라 바이오, 인크. | Sarm1 억제제로서 치환된 피리딘 유도체 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040039037A1 (en) * | 2002-06-04 | 2004-02-26 | Weijian Zhang | Heterocyclic compounds and uses thereof |
| CN1658881A (zh) * | 2002-06-12 | 2005-08-24 | 坎莫森特里克斯公司 | 抗炎组合物及其使用方法 |
| US20060217390A1 (en) * | 2005-02-24 | 2006-09-28 | Esmir Gunic | Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus |
| CN113164508A (zh) * | 2018-12-19 | 2021-07-23 | 达萨玛治疗公司 | 与神经保护剂组合的sarm1抑制剂 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA847926B (en) | 1983-10-17 | 1986-05-28 | Lilly Co Eli | 3-bicyclicpyridinium-methyl cephalosporins |
| EP0187456A1 (en) | 1984-11-29 | 1986-07-16 | Ici Pharma | Cephalosporin derivatives |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| CA2443918C (en) | 2001-04-11 | 2012-06-05 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents containing rho kinase inhibitors |
| JP2006516603A (ja) | 2003-01-27 | 2006-07-06 | ファイザー・プロダクツ・インク | イソチアゾール誘導体 |
| WO2005082001A2 (en) | 2004-02-20 | 2005-09-09 | The Scripps Research Institute | Advanced isothiazole based protein kinase inhibitors |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US7557103B2 (en) | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
| WO2006133417A1 (en) * | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
| WO2008118626A2 (en) | 2007-03-08 | 2008-10-02 | Burnham Institute For Medical Research | Inhibitors of jnk and methods for identifying inhibitors of jnk |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| US8067452B2 (en) | 2007-06-21 | 2011-11-29 | Valeant Pharmaceuticals International | 3-hydroxyisothiazole-4-carboxamidine derivatives as CHK2 inhibitors |
| US20100324049A1 (en) | 2007-09-27 | 2010-12-23 | Makoto Ando | Diaryl ketimine derivative having antagonism against melanin-concentrating hormone receptor |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Chk−1阻害剤としての6置換2−ヘテロシクリルアミノピラジン化合物 |
| WO2011019678A1 (en) | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Isothiozoles for treating conditions of the eye |
| CA2780922A1 (en) | 2010-02-11 | 2011-08-18 | OSI Pharmaceuticals, LLC | 7-aminofuropyridine derivatives |
| USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| WO2012178022A2 (en) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Therapeutic applications targeting sarm1 |
| GB201310460D0 (en) | 2013-06-12 | 2013-07-24 | Lytix Biopharma As | Compounds |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| EP4091622A1 (en) | 2016-08-16 | 2022-11-23 | Henry Ford Health System | Compositions for the treatment of chemotherapy-induced neuropathic pain |
| EP3515426A1 (en) | 2016-09-24 | 2019-07-31 | Washington University | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF |
| TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| IL251949A0 (en) * | 2017-04-26 | 2017-07-31 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Small organic molecules for use in the treatment of neuro-inflammatory diseases |
| CA3102645A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1阻害剤 |
| US12624025B2 (en) | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
-
2019
- 2019-06-06 EP EP19815890.9A patent/EP3801503A4/en active Pending
- 2019-06-06 CN CN201980052440.2A patent/CN112867489A/zh active Pending
- 2019-06-06 JP JP2021518047A patent/JP7481329B2/ja active Active
- 2019-06-06 MA MA052812A patent/MA52812A/fr unknown
- 2019-06-06 WO PCT/US2019/035846 patent/WO2019236890A1/en not_active Ceased
- 2019-06-06 US US16/972,670 patent/US12624026B2/en active Active
- 2019-06-06 CN CN202510537996.8A patent/CN120398784A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040039037A1 (en) * | 2002-06-04 | 2004-02-26 | Weijian Zhang | Heterocyclic compounds and uses thereof |
| CN1658881A (zh) * | 2002-06-12 | 2005-08-24 | 坎莫森特里克斯公司 | 抗炎组合物及其使用方法 |
| US20060217390A1 (en) * | 2005-02-24 | 2006-09-28 | Esmir Gunic | Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus |
| CN113164508A (zh) * | 2018-12-19 | 2021-07-23 | 达萨玛治疗公司 | 与神经保护剂组合的sarm1抑制剂 |
Non-Patent Citations (5)
| Title |
|---|
| AHMAD BASHEER ET AL: "A Rich Array of Reactions of Cyanomonothiocarbonylmalonamides RNHCSCH(CN)CONHR′and Their Thioenols RNHC(SH)dC(CN)CONHR′1" * |
| CHAMAKURA V. N. S. ET AL: "Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors" * |
| LAUREN J WALKER ET AL: "MAPK signaling promotes axonal degeneration by speeding the turnover of the axonal maintenance factor NMNAT2" * |
| SHAOYONG KE: "Convenient Structural Diversity-Guided Synthesis of Functionalized Sulfur-Containing Heterocycles via α-Substituted Cyanoacetamides" * |
| SHUNQI YAN ET AL: "Isothiazoles as active-site inhibitors of HCV NS5B polymerase" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023193809A1 (zh) * | 2022-04-08 | 2023-10-12 | 深圳众格生物科技有限公司 | Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3801503A1 (en) | 2021-04-14 |
| JP2021527126A (ja) | 2021-10-11 |
| CN120398784A (zh) | 2025-08-01 |
| CA3108669A1 (en) | 2019-12-12 |
| MA52812A (fr) | 2021-04-14 |
| EP3801503A4 (en) | 2021-12-08 |
| WO2019236890A1 (en) | 2019-12-12 |
| US20210261537A1 (en) | 2021-08-26 |
| JP7481329B2 (ja) | 2024-05-10 |
| US12624026B2 (en) | 2026-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112839647B (zh) | Sarm1抑制剂 | |
| CN112839648B (zh) | Sarm1抑制剂 | |
| CN113950326B (zh) | Sarm1抑制剂 | |
| Hu et al. | Cellular senescence in cardiovascular diseases: a systematic review | |
| JP7481329B2 (ja) | Sarm1阻害剤 | |
| D'Onofrio et al. | MiR-27b attenuates mitochondrial oxidative stress and inflammation in endothelial cells | |
| CN113164508B (zh) | 与神经保护剂组合的sarm1抑制剂 | |
| He et al. | A positive autoregulatory loop of Jak-STAT signaling controls the onset of astrogliogenesis | |
| CN115916764B (zh) | 作为sarm1抑制剂的吲唑衍生物 | |
| US9662314B2 (en) | Compounds and methods for the treatment of muscular disease, and related screening methods | |
| KR102359994B1 (ko) | 급성 중추 신경계 손상 질병에 대한 헥소키나제2 특이적 억제제의 응용 | |
| US20220090086A1 (en) | Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders | |
| Kang et al. | Knockdown of TRIM22 relieves oxygen–glucose deprivation/reoxygenation-induced apoptosis and inflammation through inhibition of NF-κB/NLRP3 axis | |
| KR20250006359A (ko) | Sirna 생체 이용률을 개선하기 위한 galnac 조성물 | |
| Guo et al. | Prolonged retention of albumin nanoparticles alleviates renal ischemia-reperfusion injury through targeted pyroptosis | |
| Hu et al. | Suppression of Nestin reveals a critical role for p38-EGFR pathway in neural progenitor cell proliferation | |
| KR101268478B1 (ko) | Dkk3 발현 또는 활성 억제제를 함유하는 암 예방 및 치료용 조성물 | |
| KR101384360B1 (ko) | Scf 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 | |
| US20230159935A1 (en) | CIRCULAR BIFUNCTIONAL APTAMERS AND TRIFUNCTIONAL APTAMERS TARGETING Tau | |
| Sun et al. | Antihypoxic effect of miR-24 in SH-SY5Y cells under hypoxia via downregulating expression of neurocan | |
| JP5697229B2 (ja) | 血管新生阻害剤 | |
| CN106619595A (zh) | 包含2,5‑二羟基苯磺酸的用于促进神经细胞中髓鞘再生的组合物及其用途 | |
| TW202615058A (zh) | 失養強直性肌肉蛋白質激酶(dmpk)irna組成物及其使用方法 | |
| WO2013036031A2 (ko) | microRNA486 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물 | |
| McAvoy | Non-cell Autonomous Toxicity in Motor Neuron Disease: Evidence and Mechanisms of Astrocyte-Driven Neurotoxicity in FUS-ALS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |